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The fungal type III polyketide synthase 20-oxoalkylre-
sorcylic acid synthase (ORAS) primes with a range
of acyl-Coenzyme A thioesters (C4–C20) and extends
using malonyl-Coenzyme A to produce pyrones, res-
orcinols, and resorcylic acids. To gain insight into
this unusual substrate specificity and product profile,
we have determined the crystal structures of ORAS
to 1.75 A˚ resolution, the Phe-252/Gly site-directed
mutant to 2.1 A˚ resolution, and a binary complex of
ORAS with eicosanoic acid to 2.0 A˚ resolution.
The structures reveal a distinct rearrangement of
structural elements near the active site that allows
accommodation of long-chain fatty acid esters and
a reorientation of the gating mechanism that controls
cyclization and polyketide chain length. The roles of
these structural elements are further elucidated by
characterization of various structure-based site-
directed variants. These studies establish an unex-
pected plasticity to the PKS fold, unanticipated
from structural studies of other members of this
enzyme family.
INTRODUCTION
Polyketides, a diverse class of secondary metabolites with
antibacterial and antitumor activity, are synthesized by polyke-
tide synthases (PKSs), a family of enzymes and multienzyme
complexes nearly as varied as the products they create (Austin
and Noel, 2003; Watanabe et al., 2007). In contrast to type I
and type II PKSs, which are large multidomain enzymes or multi-
subunit complexes, respectively, type III polyketide synthases
are self-contained homodimeric enzymes, where the single
active site in each monomer iteratively catalyzes the priming,
extension, and cyclization reactions needed to create a polyke-
tide product (Jez et al., 2001). In spite of their structural simplic-
ity, type III PKSs produce a wide array of compounds, including
pyrones, acridones, chalcones, stilbenes, and phloroglucinolsChemistry & Biology 15, 1079–(Schro¨der, 1999) (Figure 1). The multiplicity of products hinges
on the ability of type III PKSs to utilize a variety of acyl-CoA
thioesters for priming, to extend with varying numbers of
malonyl-CoA units, and also to cyclize the linear polyketide inter-
mediate by any of several condensation reactions. Whereas type
III PKSs from plants such as chalcone and stilbene synthase have
been studied for many years, members of this family were recog-
nized in bacteria more recently, and the first characterization of
a fungal type III PKS was reported in 2007 (Funa et al., 2007).
Filamentous fungi produce a variety of polyketide compounds,
representatives of which are both highly toxic (aflatoxin) and
pharmacologically useful (lovastatin). The known polyketide
products of filamentous fungi have thus far been traced to the
activity of type I PKSs (Cox, 2007), but putative type III PKSs
have also been uncovered by analyzing the recently sequenced
genomes of organisms including Aspergillus oryzae, Magna-
porthe grisea, and Neurospora crassa (Seshime et al., 2005).
The product of N. crassa open reading frame NCU04801.1 was
recently confirmed to be a type III PKS which prefers long-chain
acyl-CoAs for priming, carries out extension using malonyl-
CoA, and produces pyrone, resorcinol, and resorcylic acid prod-
ucts (Funa et al., 2007). Product profile analysis of this open
reading frame identifies the pentaketide resorcylic acid 20-oxoal-
kylresorcylic acid as the major product, and this enzyme was
named 20-oxoalkylresorcylic acid synthase (ORAS). ORAS is
one of several known type III PKSs to use long-chain acyl-CoA
substrates and produces tetraketide and pentaketide resorcylic
acids using C16, C18, and C20 CoA esters as starter units (Funa
et al., 2007). Alignment of ORAS and other type III PKSs of plant
and bacterial origin reveals a carboxy-terminal extension of
approximately 50 residues beyond similar enzymes (see
Figure S1 available online), and ORAS is longer than the only
other type III PKS known to have a carboxy-terminal extension,
1,3,6,8-tetrahydroxynaphthalene synthase (THNS) fromStrepto-
myces coelicolor (Izumikawa et al., 2003).
Structural analysis ofMedicagosativachalcone synthase (CHS)
(Ferrer et al., 1999), Pinus sylvestris stilbene synthase (STS) (Aus-
tin et al., 2004a), Gerbera hybrida 2-pyrone synthase (2PS) (Jez
et al., 2000), and Aloe arborescens pentaketide chromone syn-
thase (PCS) (Morita et al., 2007) from plants, and of the bacterial
enzymesMycobacterium tuberculosis Pks18 (Sankaranarayanan1090, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1079
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Structure and Function of a Pentaketide SynthaseFigure 1. Reaction Schemes of the Synthesis of Polyketides
(A) Naringenin chalcone synthesized from 4-coumaroyl-CoA and three molecules of malonyl-CoA by M. sativa CHS.
(B) 1,3,6,8-tetrahydroxynaphthalene synthesized from five molecules of malonyl-CoA by S. coelicolor THNS.
(C) Myristoyl triketide pyrone synthesized from one molecule of lauroyl-CoA and two molecules of malonyl-CoA by M. tuberculosis Pks18.
(D) Stearoyl pentaketide resorcylic acid synthesized from stearoyl-CoA and four molecules of malonyl-CoA by N. crassa ORAS.
Enzymatic decarboxylation of resorcylic acid results in the production of the product resorcinol.et al., 2004) and S. coelicolor THNS (Austin et al., 2004b) have
provided useful insight into the basis of starter molecule specific-
ity and mechanism of biosynthesis (Figure 1). Although these
enzymes share common core architectural features, subtle rear-
rangements of the polypeptide main chain and alteration of critical
residues at the active site result in the functional diversity of the
type III polyketide synthases. In order to elucidate the structural
basis for long-chain starter molecule specificity and gain insights
into the mechanism of pentaketide alkylresorcylic acid synthesis,
we have determined the crystal structures of a fully active trunca-
tion variant of ORAS to 1.76 A˚ resolution, of the Phe-252/Gly
site-directed mutant to 2.1 A˚ resolution, and of a binary complex
of truncated ORAS with eicosanoic acid (a C20 fatty acid) to 2.0 A˚
resolution. The crystal structures reveal a distinct rearrangement
of structural elements near the enzyme active site that allows
for accommodation of long-chain fatty acid esters and unique ac-
tive site features that result in a reorientation of the gating mech-
anism for controlling cyclization pattern and polyketide chain
length. These structures reveal an unexpected static nature of
the acyl-binding tunnel and suggest mechanistic similarities to
bacterial type III polyketide synthases (Sankaranarayanan et al.,
2004).
RESULTS
Expression of His-Tagged ORAS in Escherichia coli
The ORAS-encoding open reading frame NCU04801.1 was
amplified from a library of N. crassa mRNA and initially cloned1080 Chemistry & Biology 15, 1079–1090, October 20, 2008 ª2008with an amino-terminal hexahistidine affinity tag. The purified
recombinant protein was heterogeneous as judged by SDS-
PAGE analysis due to degradation of the carboxy terminus.
Consequently, the ORAS gene product was recloned with a
carboxy-terminal hexahistidine tag preceded by a thrombin
cleavage site. To determine whether the 50 residue carboxy-
terminal extension, observed upon alignment of ORAS with other
type III PKS enzymes, is necessary for catalysis, a truncated
mutant with a deletion of this extension (trORAS) was generated.
In Vitro Analysis of Recombinant ORAS
The steady-state kinetic parameters of trORAS and ORAS were
determined for the priming substrate stearoyl-CoA from initial
velocity measurements of the formation of free CoASH. Results
for recombinant ORAS (Km = 3.9 mM and kcat = 6.7 3 10
4 s1)
and trORAS (Km = 3.5 mM and kcat = 6.3 3 10
4 s1) are quite
similar, indicating that the carboxy-terminal extension is not
required for enzymatic activity. Our results reflect similar findings
obtained for a 25 residue carboxy-terminal truncated variant of
S. coelicolor THNS (see Figure S1), which was shown to possess
activity similar to that of the wild-type enzyme (Austin et al.,
2004b). Additional comparison of the specific activity and
product profile for trORAS and ORAS is provided in Figure S3.
Structural Rearrangements in the Lower Domain
of ORAS
Crystallization attempts of full-length ORAS were hampered by
the propensity of the enzyme to degrade over the course ofElsevier Ltd All rights reserved
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Structure and Function of a Pentaketide SynthaseTable 1. Data Collection, Phasing, and Refinement Statistics
Native ORAS SeMet ORAS F252G ORAS Eicosanoic Acid
Data Collection
Space group P212121 P212121 P21 P21
Unit cell dimensions
a, b, c (A˚) 69.7, 105.0, 105.3 68.5, 103.0, 105.6 69.7, 105.1, 105.1 68.9, 105.9, 104.1
a, b, g () 90.0, 90.0, 90.0 90.0, 90.0, 90.0 90.0, 90.3, 90.0 90.0, 90.1, 90.0
Resolution (A˚)a 50–1.75 (1.86–1.75) 50–2.2 (2.28–2.2) 50–2.1 (2.18–2.1) 50–2.0 (2.07–2.0)
Rsym (%)
b 11.2 (56.2) 6.5 (17.9) 7.1 (29.3) 8.1 (29.1)
I/s (I) 11.3 (2.9) 37.1 (8.9) 17.2 (3.3) 16.4 (4.8)
Completeness (%) 97.9 (92.4) 98.1 (97.5) 96.3 (90.1) 97.0 (88.7)




Resolution (A˚) 25.0–1.75 25.0–2.1 25.0–2.0
Number of reflections 74,247 80,720 92,963
Rwork/Rfree
d 17.9/20.9 19.8/25.6 17.4/22.5
Number of atoms
Protein 5,698 11,368 11,396
Solvent 733 824 805
PEG 0 38 0
Eicosanoic acid 0 0 44
Average B value
Protein 17.6 27.8 30.3
Solvent 29.1 30.3 38.9
Ligand 43.0 50.4
Rms deviations
Bond lengths (A˚) 1.16 1.29 1.19
Bond angles () 0.008 0.010 0.012
a Highest resolution shell is shown in parentheses.
b Rsym = Sj(Ii  < Ii >)jSIi, where Ii = intensity of the ith reflection and < Ii > = mean intensity.
c Mean figure of merit before and after density modification.
d R factor = S(jFobsj  kjFcalcj)/SjFobsj and R free is the R value for a test set of reflections consisting of a random 5% of the diffraction data not used in
the refinement.a few hours following purification. Mass spectrometric analysis
of the degradation product suggested cleavage at residues
located at the charged carboxy-terminal extension. Limited
proteolysis confirmed that the residues at the carboxy terminus
are labile and, as the variant lacking carboxy-terminal extension
residues is shown to be fully catalytically competent, crystalliza-
tion efforts were focused on this deletion variant.
Screening of this truncated ORAS readily produced crystals
utilizing polyethylene glycol 8000 as a precipitant. As attempts
to solve the structure of trORAS by molecular replacement using
the coordinates of other type III polyketide synthases were not
successful, crystallographic phases were determined de novo
using single-wavelength anomalous scattering from crystals
grown from selenomethionine-incorporated protein. The resultant
electron density map was of exceptional quality, permitting a trace
of all residues from Ala-9 through Arg-388 in each monomer and
refinement against a 1.75 A˚ resolution data set to a final R factor/
free R factor of 17.9%/20.8% (see Table 1 for further details).Chemistry & Biology 15, 1079–1The overall structure of trORAS recapitulates the characteris-
tic bidomain fold observed in structures of other type III
polyketide synthases (Jez et al., 2001), albeit with novel distin-
guishing structural elements (Figure 2A). A structure-based
similarity search using the Dali search engine (Holm and Sander,
1995) queried against the Protein Data Bank (Berman et al.,
2000) identifies chalcone synthase (Ferrer et al., 1999) as the
closest structural homolog (Z score = 46.9, root-mean-square
deviation [rmsd] of 2.2 A˚ over 355 residues aligned with a
sequence identity of 24%). Two other homologs of note, which
share a significant characteristic structural feature with ORAS
(see below), are the bacterial type III PKS enzymes, particularly
S. coelicolor THNS (Austin et al., 2004b) (Z score = 42.8, rmsd
of 2.3 A˚ over 344 residues aligned with a sequence identity of
24%), and M. tuberculosis Pks18 (Sankaranarayanan et al.,
2004) (Z score = 44.2, rmsd of 2.2 A˚ over 346 residues aligned
with a sequence identity of 24%) (see Figure 2B for a structure-
based sequence alignment).090, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1081
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Structure and Function of a Pentaketide SynthaseAlthough the core structure of trORAS is characteristic of that
of other type III PKSs, the structure is set apart by significant
deviations in the backbone relative to other enzymes of this fam-
ily. The core ababa thiolase fold observed in the upper domains
of type III PKS molecules is retained in the structure of trORAS,
albeit with uncharacteristically long loop regions that vary in
length in comparison with the closest structural homologs.
Within one such loop region, the polypeptide backbone between
a helix a12 and b sheet b12 adopts an a-helical configuration
spanning residues Asp-355 through Leu-359.
The fold of the lower domain of trORAS, harboring the tradi-
tional ‘‘floor’’ of the type III PKS active site and containing
residues that are thought to be critical for substrate and product
specificities, is significantly different from that observed in other
family members. Most notably, in comparisons with the struc-
tures of other type III PKSs, the loop that bridges helices a4 and
a5 is shortened by about six amino acids, resulting in a depres-
sion at this juncture of the polypeptide fold. This shorter loop is
compensated by an extension of residues Thr-188 through
Gln-201 into the corresponding void. Unexpectedly, in this
Figure 3. Close-Up View of the Active Site
of trORAS
(A and B) Ribbon diagram of the lower domains of
(A) ORAS in blue and (B) CHS in green with bound
malonyl-CoA (shown in ball-and-stick representa-
tion) highlighting the topological differences in this
region of the active site. The a7 insertion present in
ORAS is shown in yellow.
(C and D) Stick-figure representations of residues
that are believed to be involved in catalysis and
product/substrate specificity in the active sites of
(C) ORAS and (D) CHS complexed with naringenin.
The phenylalanine residues that function as steric
gates to control specificity are colored in blue, and
residues that are implicated in participating in
mechanistic steering of intermediates are shown
in orange.
region, residues Met-189 through Asp-
198 form an a-helical insertion that
bridges sheets b6 and helix a8 (Figures
3A and 3B). This novel structural element,
which we term insertion a7i, has not to
our knowledge been previously observed
in any type III PKS enzyme. In order to
compensate for this helical insertion, the
helix that follows this insertion (a8) and
typically spans nine residues (Leu-206
through Leu-214 in M. sativa CHS) (Ferrer
et al., 1999) has been shortened to
encompass only four residues in trORAS
(Gly-206 through Leu-209) (Figures 3A and 3B). These novel
structural elements result in a rearrangement of the lower
domain at the floor of the active site, and the functional ramifica-
tions of this rearrangement are discussed below.
Active Site Architecture
As observed in crystal structures of related type III PKS
enzymes, trORAS exists as an obligate homodimer and, upon
dimerization, each monomer buries 2364 A˚2 of surface area.
However, trORAS lacks the amino-terminal helical extension
that crosses over between the two monomeric units as in the
structures of M. sativa CHS (Ferrer et al., 1999) and A. arbores-
cens PCS (Morita et al., 2007). In addition, trORAS lacks the
Met-137 residue of M. sativa CHS that is highly conserved in
plant type III PKS and participates in intersubunit contacts by
protruding into the neighboring monomer to complete the com-
posite active site. Instead, an asparagine residue (Asn-125) is
located at the equivalent position, resulting in a lack of cross-
subunit interactions in the formation of the active site cavity.
The opening at the active site that is required for the intersubunitFigure 2. Overall Structure of trORAS and Multiple Sequence Alignment
(A) Ribbon diagram derived from the crystal structure of trORAS, with one monomer colored in blue and the other colored in magenta. In the lower domain of each
monomer, residues Met-189 through Asp-198 form an a-helical insertion that bridges sheets b6 and helix a8. This novel structural element, which has not to our
knowledge been previously observed in any type III PKS enzyme, is termed insertion a7i and is shown in yellow.
(B) Structure-based sequence alignment of ORAS with other bacterial and plant type III polyketide synthases of note, including M. sativa CHS, M. tuberculosis
Pks18, S. coelicolor THNS, and A. arborescens PCS. Residues that constitute the catalytic triad are shown with an asterisk.Chemistry & Biology 15, 1079–1090, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1083
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by a reorganization of the backbone between His-148 and
Cys-152. A similar situation is observed in the structure of
M. tuberculosis Pks18 that contains Ala-148 at the equivalent
position and a substitution of the glycine residue at the opening
by a leucine that similarly occludes cross-subunit interactions
(Sankaranarayanan et al., 2004).
The catalytic triad, consisting of Cys-152, His-305, and
Asn-338, is situated at a location and orientation similar to that
observed in other related type III PKS enzymes (Figures 3C and
3D). Mutation of Cys-152 to threonine was performed on the
truncated ORAS enzyme to confirm the identity of this residue
as the catalytic cysteine. The substitution resulted in loss of
activity, with no product observed after 1.5 hr incubation in the
presence of substrate (see Figure S6). As observed in the struc-
tures of M. sativa CHS (Ferrer et al., 1999) and G. hybrida 2PS
(Jez et al., 2000), the electron density at Cys-152 is consistent
with the oxidation of this residue into sulfuric acid. Despite
considerable efforts, cocrystallization attempts with long- and
medium-chain fatty acyl-CoA esters have not been successful.
Of note is the fact that ORAS is devoid of any of the positively
charged residues that have been observed to line the CoA-
binding pockets of other bacterial and plant type III PKSs where
they stabilize the charges on the phosphopantetheine. The lack
of these stabilizing elements in ORAS may account for the inabil-
ity to obtain a static binary complex in the time courses required
for cocrystallization.
In addition to the active site cysteine (Cys-152) that presents
the covalent attachment site necessary for polyketide chain
extension (Austin and Noel, 2003; Jez et al., 2001), ORAS also
harbors a second cysteine residue (Cys-120) at a position equiv-
alent to that of Cys-106 in S. coelicolor THNS (Abe et al., 2005b).
In this bacterial enzyme that catalyzes a malonyl-CoA-primed
pentaketide formation, Cys-106 is presumed to regulate polyke-
tide reactivity either by facilitating the enolization of the triketide
carboxylate, by protonation of the triketide enolate, or by hemi-
thioketal formation during the elongation stage. Site-directed
mutagenesis of this cysteine results in derailment of polyketide
elongation and in the formation of a triacetic acid lactone (Abe
et al., 2005b). The equivalent cysteine in trORAS (Cys-120) was
mutated to serine to investigate the role of this residue.
The Cys-120/Ser mutant diminished but did not abolish
resorcinol production, and the decrease in activity due to this
mutation was more pronounced for longer acyl-CoA substrates
(Figures S4–S6).
In the structure of trORAS, Cys-120 occupies a position anal-
ogous to Thr-132 in P. sylvestris stilbene synthase (STS) (Austin
et al., 2004a) and M. sativa CHS (Ferrer et al., 1999). Prior crys-
tallographic and biochemical analysis demonstrates that the
positioning of this residue is critical to the formation of a thioes-
terase-like hydrogen-bonding network that mediates aldol cycli-
zation specificity (Austin et al., 2004a). This CHS/STS ‘‘aldol
switch’’ controls the partitioning of the tetraketide intermediate
between two competing chemical paths. Analysis of the active
site structure of trORAS reveals that the orientation of Cys-120
is similar to that of Thr-132 in CHS and precludes the formation
of a thioesterase-like hydrogen-bonding network for partitioning
of intermediates. Consequently, the mechanism for aldol con-
densation and aromatization by trORAS proceeds through1084 Chemistry & Biology 15, 1079–1090, October 20, 2008 ª2008a yet unidentified mechanism distinct from that of STS. In
addition, alkylresorcinols are among the products identified for
trORAS both in this and in prior studies (Funa et al., 2007; Goyal
et al., 2008), suggesting that the stable resorcylic acid is an
intermediate that is further enzymatically decarboxylated by
ORAS to yield the final alkylresorcinol product. The production
of this carboxylated resorcylic acid intermediate by ORAS further
distinguishes the mechanism of this enzyme from STS, which
does not produce a stilbene carboxylate intermediate (Austin
et al., 2004a).
A Reorganized Steric Gate Controls Specificity
Prior biochemical and structural studies on plant and bacterial
type III PKSs have established the importance of several resi-
dues near the active site in controlling substrate and product
specificities, including Thr-197, Gly-256, and Ser-338 of M. sat-
iva CHS. In the structure of ORAS, drastic rearrangements at the
active site result in significantly deviant dispositions of residues
Phe-252 (corresponding to Gly-256) and Met-189 (correspond-
ing to Thr-197) (Figures 3C and 3D). Specifically, the replace-
ment of the smaller side chain of Thr-197 in M. sativa CHS with
the larger Met-189 in ORAS is compensated by significant
expansion of the polypeptide backbone in this region as a result
of the a7i helical insertion. Consequently, this substitution actu-
ally results in an increase in the active site contour along the
backbone at this region. This is in contrast with results obtained
for pentaketide chromone synthase (PCS) and octaketide
synthase (OKS) from A. arborescens, where the residue at the
analogous position plays a crucial role in controlling product
chain length. Replacement of Gly-207 in OKS with larger side
chains results in a smaller active site cavity and alters specificity
toward smaller pentaketide products (Abe et al., 2005a),
whereas replacement of Met-207 in PCS with smaller side chains
(Abe et al., 2005b) increases the active site cavity of this enzyme
and alters specificity to larger octaketide products. Surprisingly,
mutation of the larger side chain of Met-189 in ORAS with
threonine results in significant loss of activity without alterations
to the product profile (Figure S8). These data suggest a role for
the side chains of Met-189 in orienting substrates in the active
site, consistent with the observed binding mode for fatty acids
in the trORAS-eicosanoic acid cocrystal structure (see later
section for details).
The reorganization of the polypeptide backbone near Met-189
results in a compensatory movement of the flanking b sheet (b9
encompassing residues Leu-250 through Asp-255) into the
resultant cavity. In addition, the glycine residue that occupies
a critical position along this strand (Gly-256 in M. sativa CHS)
is replaced with Phe-252 in ORAS, further constricting the walls
of the active site along this face of the tunnel (Figures 3C and 3D).
As a consequence of these structural reorganizations, Phe-252
is now poised to serve as a steric gate to regulate product
specificity, in a manner analogous to the role played by Gly-
207 in OKS (Abe et al., 2005a) and Met-207 in PCS (Abe et al.,
2005b). Substitution of Phe-252 to glycine in the trORAS enzyme
altered the product profile for long-chain acyl-CoA substrates
(C16 or larger) and specifically disrupted the production of penta-
ketide resorcinol and resorcylic acid products. With palmitoyl-
CoA 5a (C16) and monounsaturated oleoyl-CoA 6a (C18) as
substrates, minor pentaketide products 5h, 6g, and 6h observedElsevier Ltd All rights reserved
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mutant. The effect was most significant for stearoyl-CoA 7a
(C18) and arachidoyl-CoA 8a (C20)-primed reactions, which
resulted in increased abundance of pyrone derailment products
including hexaketide (7i, 8i) and heptaketide (7j, 8j) pyrones at
the expense of the pentaketide resorcinol product (7h, 8h)
(Figure 4). Taken together, these results suggest that the length
and flexibility of very long (C18 and C20) saturated acyl-CoAs
allow for extensive interactions along the hydrophobic tunnel
Figure 4. Overview of Reactions Catalyzed
by trORAS and the Phe-252/Gly Mutant
Products confirmed by LC-MS/MS for trORAS are
shown in red, those for the Phe-252/Gly mutant
are shown in blue, and products observed for both
enzymes are shown in green. Mass spectral
analysis of these products is provided in Table S2.
of the enzyme, where Phe-252 may play
a role in stabilizing the extended linear
polyketide chain such that enzymatic
resorcinol production will be favored
over lactonization in solution.
Structure of the Phe-252/Gly
Mutant
In order to confirm that the altered prod-
uct profile of the Phe-252/Gly mutant
is not a consequence of gross structural
alterations, the crystal structure of this
variant was determined to 2.1 A˚ resolu-
tion, using the coordinates of the unli-
ganded enzyme as a search probe (final
R factor/free R factor of 19.8%/25.5%).
The overall structure of this variant is
almost identical to that of the wild-type
enzyme except that unbiased electron
density maps clearly show the substitu-
tion of Phe-252 by Gly (Figure 5A). Inter-
estingly, clear but discontinuous density
can be observed near the active sites in
two of the four molecules in the crystallo-
graphic asymmetric unit of this variant,
and this has been modeled as a molecule
of polyethylene glycol (presumably car-
ried over from the crystallization media)
(Figure 5A). The larger cavity created in
the vicinity of the active site as a conse-
quence of this mutation more easily
accommodates the polyethylene glycol,
and a similar ligand is also observed in
the structure of S. coelicolor THNS
(Austin et al., 2004b).
The removal of the bulky aromatic side
chain from the hydrophobic core of the
active site does not compromise packing
integrity, and there are minimal perturba-
tions of either of the main-chain atoms as
a consequence of the Phe-252/Gly mutation. The rmsd of
main-chain atoms between wild-type and Phe-252/Gly trO-
RAS is only 0.2 A˚. Whereas the main-chain atoms of wild-type
trORAS and the Phe-252/Gly mutant can be accurately super-
imposed, the side-chain atoms of a number of residues in the
vicinity of Gly-252 are altered as a consequence of the mutation.
Specifically, the side chains of active site residues Cys-152,
Phe-210, Met-189, and a number of additional flanking residues
are slightly displaced relative to their positions in the wild-typeChemistry & Biology 15, 1079–1090, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1085
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Structure and Function of a Pentaketide SynthasetrORAS structure (Figure 5B). The lack of any gross structural
perturbations as a consequence of the Phe-252/Gly mutation
suggests that the derailment of polyketide extension in this
variant is a direct consequence of alterations in the activity site
cavity, consistent with the role of Phe-252 as a steric regulator
of product specificity in ORAS.
Figure 5. Active Sites of trORAS and the Phe-252/Gly Mutant
(A) Electron density map (shown in blue mesh and contoured at 2.5s) calcu-
lated using Fourier coefficients Fobs  Fcalc with phases derived from the final
refined model of Phe-252/Gly trORAS minus the atoms of residue Gly-252
and all active site ligands. Clear, but discontinuous, electron density can be
observed near the vicinity of Gly-252 and has been modeled as a molecule
of polyethylene glycol. The final refined coordinates of important active site
residues are shown as stick figures, the polyethylene glycol is shown in pink.
(B) A superposition of active site residues of wild-type trORAS (shown in pink)
and the Phe-252/Gly variant (shown in blue). There are no significant
changes in the main-chain atoms of the two structures and only small
alterations in the position of the active site residues are shown.1086 Chemistry & Biology 15, 1079–1090, October 20, 2008 ª2008A Static Acyl-Binding Tunnel Flanks the Elongation/
Extension Site
The active site cavity of ORAS is flanked by an acyl-binding tun-
nel similar to those observed in the structures of the bacterial
type III PKSs M. tuberculosis Pks18 and S. coelicolor THNS
(Austin et al., 2004b; Sankaranarayanan et al., 2004). Although
attempts to obtain cocrystals with various CoA esters failed,
cocrystallization efforts of trORAS with long-chain fatty acids
yielded diffraction-quality crystals, and the structure of a binary
complex with eicosanoic acid (a C20 fatty acid) has been deter-
mined to 2.0 A˚ resolution by molecular replacement, using the
coordinates of the unliganded enzyme as a search probe (final
R factor/free R factor of 17.3%/22.5%). Initial, unbiased electron
density maps, calculated after a cycle of crystallographic refine-
ment of the molecular replacement solution, revealed strong and
continuous electron density corresponding to the entire C20 fatty
acid in two of the four molecules in the crystallographic
asymmetric unit (corresponding to one ligand per biological
dimer) (Figures 6A and 6B).
The eicosanoic acid C20 fatty acid chain occupies a position
similar to that observed for a myristic acid ligand in the structure
of M. tuberculosis Pks18 (Sankaranarayanan et al., 2004) and
a heptamer of polyethylene glycol in the structure of S. coelicolor
THNS (Austin et al., 2004b) (Figures 6C–6E). In the trORAS
cocrystal structure, as in each of the bacterial type III PKSs,
the ligand occupies a long acyl-binding tunnel that extends
into the ‘‘floor’’ of the PKS active site. However, the carboxyl
group of the eicosanoic acid ligand is significantly closer to the
two active site cysteines of trORAS (Cys-152 Sg-O distance of
4.2 A˚; and Cys-120 Sg-O distance of 4.0 A˚) than observed for
the distance between the ligands and the nucleophilic cysteine
in either of the bacterial enzymes (Austin et al., 2004b; Sankara-
narayanan et al., 2004). Although the Sg carboxylate oxygen
distances are far too large to suggest covalent linkages, the
distance and stereochemical disposition between the carboxyl
group of the fatty acid and the two cysteines are consistent
with the mechanism of steering polyketide reactivity as sug-
gested by biochemical studies of S. coelicolor THNS (Austin
et al., 2004b; Sankaranarayanan et al., 2004).
In the trORAS cocrystal structure, the location of the hydro-
phobic fatty acid tail of the eicosanoic acid ligand is distinct
from that observed for ligand complexes of the bacterial type
III PKSs (Austin et al., 2004b; Sankaranarayanan et al., 2004).
The hydrocarbon tail does not extend out into bulk solvent but
rather is directed back inward into the protein and toward the di-
mer interface (Figures 6C–6E). The trajectory of the hydrocarbon
tail is restricted by the a7i helical insertion, which blocks the base
of this lower domain of trORAS and guides the ligand back into
the protein and away from bulk solvent. A key structural element
that orients the hydrocarbon tail is the side chain of Met-189,
which forms one side of the wall of the ligand-binding cavity.
Mutational analysis demonstrates that replacement of Met-189
with a smaller threonine side chain significantly compromises
catalytic activity with smaller-chain acyl-CoAs (Figure S8),
consistent with a role of this residue in guiding the binding of
hydrocarbon tails of the fatty acid substrates.
During the review process for this manuscript, an independent
report of the structure of unliganded ORAS was published by
Sankaranarayanan and colleagues (Goyal et al., 2008). AlbeitElsevier Ltd All rights reserved
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Structure and Function of a Pentaketide SynthaseFigure 6. Close-Up View of the Active Site of trORAS Bound to Eicosanoic Acid
(A and B) Orthogonal views of an electron density map (shown in blue mesh and contoured at 2s) calculated using Fourier coefficients Fobs  Fcalc with phases
derived from the final refined model of the ORAS-eicosanoic acid complex minus the atoms of the eicosanoic acid ligand. The final refined coordinates of
important active site residues are shown as stick figures, the eicosanonic acid is shown in pink, and the a7 insertion is shown as a ribbon diagram in red.
(C–E) Ribbon diagrams derived from the crystal structures of (C) trORAS (shown in blue) with bound eicosanoic acid, (D) Pks18 (shown in cyan) with bound
myristic acid, and (E) THNS (shown in pink) with a bound molecule of polyethylene glycol. Each of the ligands is shown as CPK models and the respective active
site cysteine residues are shown in ball-and-stick representation.of significantly lower resolution, the overall fold of the polypep-
tide is similar to that detailed in our 1.8 A˚ resolution structure
of trORAS. However, these investigators fail to note the a7i
helical insertion that distinguishes the reorganized active site of
ORAS from other type III PKSs such as chalcone synthase (Fer-
rer et al., 1999). In addition, poststructural biochemical analysis
carried out by these investigators is based on a model of the fatty
acid binding site derived from the structure of the bacterialChemistry & Biology 15, 1079–M. tuberculosis Pks18 bound to myristic acid (Sankaranar-
ayanan et al., 2004). However, our 2.0 A˚ resolution cocrystal
structure of trORAS bound to eicosanoic acid reveals that the
trajectory of the hydrocarbon tail is distinct from that observed
in the Pks18-myristic acid structure, and this novel fatty acid-
binding tunnel is created by virtue of the a7i helical insertion
(Figures 6C–6E). Consequently, mutational analyses of ORAS
based on the Pks18 cocrystal structure are likely not particularly1090, October 20, 2008 ª2008 Elsevier Ltd All rights reserved 1087
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sterically occlude the incorrectly identified substrate-binding tun-
nel (Ser-186/Phe) showed no changes in substrate preference
(Goyal et al., 2008). A second double variant (Ser-186/Phe/
Ser-340/Leu) was unable to synthesize any products from
either short- or long-chain fatty acids (Goyal et al., 2008), and
this is likely a consequence of the fact that Ser-340 is immedi-
ately adjacent to the catalytic nucleophile (Cys-152) and
mutations at this residue will likely interfere with substrate bind-
ing regardless of the chain length of the starter unit. The cocrystal
structures presented in this current work and the corresponding
mutational analyses unambiguously define a unique binding site
for the long-chain hydrocarbon tail that distinguishes ORAS from
other type III polyketide synthases.
The structures of the unliganded trORAS and the trORAS-ei-
cosanoic acid complex are nearly identical and only small, subtle
rearrangements of secondary structural elements along the
atoms of the hydrocarbon tail are necessary to accommodate
the ligand into the acyl-binding pocket. This is in sharp contrast
with studies of S. coelicolor THNS and plant type III PKSs that
suggest that the acyl-binding tunnel is dynamic and likely
undergoes progressive, motional displacement during the
extension of the aliphatic tail of polyketide intermediates (Austin
et al., 2004b; Austin and Noel, 2003). Particularly noteworthy is
the fact that for each of the bacterial type III PKSs that harbors
a bound ligand in the acyl-binding pocket, the ligand serendipi-
tously either copurified with protein or was a product of the crys-
tallization medium. No structures of these proteins are available
in both the absence and presence of ligand (Austin et al., 2004b;
Sankaranarayanan et al., 2004). In contrast, our structure of
wild-type unliganded trORAS is devoid of any extraneous
ligands, and density for eicosanoic acid is present only when
the ligand is explicitly introduced into the crystallization medium.
These results have been reinforced by our observations of an
unoccupied acyl-binding pocket in structures derived from
over two dozen different data sets collected during the course
of this work. The presence of a static acyl-binding tunnel may
be a unique feature of this fungal type III PKS that distinguishes
this enzyme from the bacterial enzymes. Alternatively, a well-
defined tunnel may be characteristic of all type III PKS enzymes
that utilize long-chain acyl-CoA esters as starter molecules.
Further biochemical experiments are currently under way to
distinguish between these possibilities.
SIGNIFICANCE
The 20-oxoalkylresorcylic acid synthase (ORAS) of N. crassa
is the only known type III polyketide synthase that can
produce pentaketide resorcylic acids. The enzyme utilizes
a long-chain fatty acid CoA ester starter molecule and car-
ries out sequential condensations with four molecules of
malonyl-CoA to yield the resorcylic acid. Our structural anal-
ysis of a truncatedORASmutant reveals a unique rearrange-
ment of secondary structural elements in the lower domain
of the enzyme and a reorientation of the gating mechanism
for controlling polyketide chain length and cyclization pat-
tern. Similar to bacterial type III polyketide synthases, this
fungal enzyme harbors a second active site thiol that may
function in the mechanism of steering polyketide reactivity.1088 Chemistry & Biology 15, 1079–1090, October 20, 2008 ª2008In the cocrystal structure of trORAS with the C20 fatty acid
eicosanoic acid, the hydrocarbon tail is accommodated
within the protein interior within an extended acyl-binding
pocket with a novel trajectory that results from the reorgan-
ized lower domain. The structure reveals an unexpected
mechanism for sequestering large acyl groups that may be
shared among other type III PKSs that utilize long-chain fatty
acid CoA esters as starter molecules. These studies estab-
lish a framework for further engineering experiments aimed
at exploiting the diversity of type III PKSs.
EXPERIMENTAL PROCEDURES
Cloning
A complete listing of primers is given in Table S1. Open reading frame
NCU04801.1 (ORAS) was amplified from a library of N. crassa mRNA by re-
verse-transcription PCR in two steps using the First Strand cDNA synthesis
kit (Roche Applied Sciences, Mannheim, Germany) and the specific primers
FWD1 and REV1, followed by PCR amplification using the same primers.
The resulting DNA product was restriction digested and inserted into
pET15b to yield pET15b-ORAS. Subsequently, NCU04801.1 was reamplified
using the above forward primer and a new reverse primer, REV2, and the
resultant PCR product was digested and ligated into pET26b to yield pET26-
trORAS. A thrombin protease site was engineered into the reverse primer in
order to facilitate cleavage of the carboxy-terminal hexahistidine tag. A
carboxy-terminal truncation variant of ORAS (trORAS) was amplified using
the above forward primer and the reverse primer REV3, restriction digested,
and ligated into pET15b to yield pET15b-trORAS. The DNA sequence of all
constructs was verified. DNA sequencing was performed at the University of
Illinois Biotechnology Center (Urbana, IL, USA).
Expression and Purification of Recombinant ORAS and trORAS
Plasmids pET26b-ORAS, pET15b-ORAS, and pET15b-trORAS were trans-
formed into E. coli BL21 (DE3) and single colonies were used to inoculate 5 ml
Luria broth containing 50 mg kanamycin/ml (pET26b) or 100 mg ampicillin/ml
(pET15b). Following overnight growth at 37C, this culture was used to inocu-
late 500 ml Terrific broth containing the appropriate antibiotic, and grown at
37C until the optical density at 600 nm reached 0.8. Protein expression was
induced with the addition of 0.25 mM isopropyl-b-D-thiogalactopyranoside
(IPTG), and growth was continued for an additional 18 hr at 25C. The flasks
were chilled for 30 min, and then the cells were harvested by centrifugation
(6000 3 g, 4C, 15 min). The resulting pellet was resuspended in 2 ml lysis
buffer (10 mM imidazole, 50 mM sodium phosphate buffer, 300 mM NaCl,
15% glycerol [pH 8.0], 1 mg/ml lysozyme) per gram cell weight and frozen at
–80C. Subsequently, cells were lysed using a French press and cellular debris
was removed by centrifugation (40,0003 g, 4C, 10 min, twice). Recombinant
proteins were purified by chromatography on Ni-NTA resin by virtue of the
engineered carboxy-terminal (wild-type ORAS) or amino-terminal (trORAS)
hexahistidine affinity tag. Captured protein was washed with wash buffers
(20, 30, and 50 mM imidazole, 50 mM sodium phosphate buffer, 300 mM
NaCl, 15% glycerol [pH 8.0]) and finally eluted in elution buffer (100 mM imid-
azole, 50 mM sodium phosphate buffer, 300 mM NaCl, 15% glycerol [pH 8.0]).
The protein content of individual elution fractions was estimated using the
Quick Start Bradford protein assay (Bio-Rad, Hercules, CA, USA) and the
appropriate fractions were pooled and buffer exchanged into 10 mM MOPS
buffer (pH 7.5) containing 15% glycerol overnight at 4C. The protein was con-
centrated using an Amicon ultracentrifugal filter device (Millipore, Billerica, MA,
USA). Representative SDS-PAGE analysis of recombinant protein is shown in
Figure S2. The hexahistidine tags were removed using the Thrombin Cleavage
Capture kit (Novagen, Madison, WI).
Determination of Kinetic Parameters
Experiments to determine the kinetic parameters of wild-type and truncated
ORAS enzyme with stearoyl-CoA were carried out in triplicate. Experiments
were conducted according to the method of Funa et al. (2007) with some mod-
ifications. Each reaction contained 50 mM Tris-HCl (pH 7.0), 0.5 mMElsevier Ltd All rights reserved
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action volume of 400 ml. The concentration of priming acyl-CoA was varied be-
tween 0.5 and 10 mM stearoyl-CoA. Reaction mixtures were preincubated at
30C for 4 min before addition of malonyl-CoA. After mixing, a 100 ml aliquot
of the reaction was removed and stopped immediately by addition of 20 ml
of a solution of 4% trifluoroacetic acid in water. Subsequently, a second ali-
quot was removed at 45 s and quenched by the same method. Samples
were kept at 4C until analysis by HPLC. The reactions were analyzed using
an Agilent 1100 Series HPLC and ZORBAX SB-C18 reverse-phase column
(3.03 150 mm, 3.5 mm) (Agilent Technologies, Palo Alto, CA, USA) monitoring
at 258 nm, with conditions as follows: 0.5 ml/min; 25C; solvent A: 15 mM am-
monium formate; solvent B: 90% methanol, 10% 10 mM ammonium acetate
(pH 7.3), adjusted using acetic acid; 0–15 min, 5%–20% B, 15–20 min,
20%–100% B, 20–27 min, 100% B. Peaks at 7 min and 9.5 min corresponded
to authentic malonyl-CoA and CoASH, respectively. The initial rates of CoASH
production determined from these reactions were fitted to the Michaelis-
Menten equation using nonlinear least-squares regression analysis in Microcal
Origin 5.0 (Microcal Software, Northampton, MA, USA) to calculate kcat
and KM.
Preparation of ORAS Mutants and Product Profile Analysis
Site-directed mutants were created using the QuikChange Site-Directed
Mutagenesis kit (Stratagene, La Jolla, CA, USA). From the pET15b-trORAS
plasmid, the primers 252-F and 252-R were used to generate the Phe-
252/Gly mutant, 152-F and 152-R were used to generate the Cys-152/
Thr mutant, and 120-F and 120-R were used to generate the Cys-120/Ser
mutant. The DNA sequence of each mutant was verified and the mutants
were expressed by the same method as described for ORAS and trORAS.
Reactions for product profile analysis contained 50 mM Tris-HCl (pH 7.0),
4 mM recombinant protein (ORAS, trORAS, or mutant), and the concentration
of priming acyl-CoA and malonyl-CoA was 200 mM in a total reaction volume of
250 ml. Reaction mixtures were incubated at 30C for 1.5 hr followed by HPLC
analysis as described in Supplemental Experimental Procedures. The polyke-
tide products were characterized by liquid chromatography-quadrupole
time-of-flight mass spectrometry on a Micromass Q-Tof Ultima (Waters,
Milford, MA, USA). Mass spectrometry was performed at the University of
Illinois Mass Spectrometry Laboratory (Urbana, IL, USA).
Crystallization
For crystallization efforts, truncated ORAS (trORAS) and the Phe-252/Gly
mutant of truncated ORAS were purified as described above, and its amino-
terminal polyhistidine tag was removed using thrombin (1 U/mg protein; GE
Healthcare, Piscataway, NJ, USA). The protein was further purified by anion-
exchange (5 ml HiTrap Q; GE Healthcare) and size-exclusion chromatogra-
phies (Superdex 75 16/60; GE Healthcare). Selenomethionine-incorporated
trORAS (SeMet trORAS) was produced by the method of van Duyne et al.
(1993) and purified as described, except that 5 mM DTT was included in all
of the buffers.
Crystals of native and SeMet trORAS and the Phe-252/Gly mutant were
grown by the hanging-drop vapor-diffusion method. In each case, 1.5 ml pro-
tein (5 mg/ml) was mixed with 1.5 ml precipitant solution containing 18% poly-
ethylene glycol 8000, 100 mM HEPES (pH 7.5), with 1% polyethylene glycol
3350 as an additive. The mixture drop was equilibrated over a well containing
the same precipitant solution at 20C, and crystals reached their maximum
size after 3 days. Crystals that diffracted to slightly higher resolutions could
be produced by incubation at 4C, but these crystals took several weeks to
grow and were not easily reproduced. Hence, initial phase determination
utilized crystals grown at 20C and subsequent crystallographic refinement
was conducted against data collected from a crystal grown at 4C. Crystals
were briefly immersed in a solution consisting of the crystallization liquor
supplemented with 25% glycerol, prior to vitrification by immersion in liquid
nitrogen. For crystallization of ligand complexes, the appropriate ligand was
added to the protein to a final concentration of 2–5 mM prior to crystallization.
Phasing and Structure Determination
A four-fold redundant data set was collected from orthorhombic crystals of
selenomethionine-substituted trORAS at the selenium absorption edge, to
a limiting resolution of 2.0 A˚ (overall Rmerge = 8.6, I/s (I) = 2.4 in the highestChemistry & Biology 15, 1079–resolution shell) utilizing a Mar 300 CCD detector (LS-CAT, Sector 21 ID-D,
Advanced Photon Source, Argonne, IL, USA). The structure of trORAS was
solved by single-wavelength anomalous diffraction utilizing anomalous scat-
tering from the 14 selenium-substituted methionine residues per monomer.
Data were indexed and scaled using the HKL2000 package (Otwinowski
et al., 2003). Selenium sites were identified using HySS (Grosse-Kunstleve
and Adams, 2003) and the heavy-atom substructure was imported to SHARP
(Bricogne, et al., 2003) for maximum-likelihood refinement and phase calcula-
tion, yielding an initial figure of merit of 0.425 to 2.2 A˚ resolution. Solvent
flattening using DM (Cowtan and Main, 1998) further improved the quality of
the initial map (solvent-flattened figure of merit = 0.696). The resultant electron
density map was of exceptional quality and permitted most of the main-chain
and 75% of side-chain residues to be automatically built using ARP/wARP
(Perrakis et al., 1997). The remainder of the model was fitted using XtalView
(McRee, 1999) and further improved by rounds of refinement with REFMAC5
(Murshudov et al., 1997, 1999) and manual building. Subsequent rounds of
model building and crystallographic refinement utilized data from a crystal
of trORAS grown under similar conditions at 4C that diffracted to 1.75 A˚
resolution (overall Rmerge = 7.7, I/s [I] = 4.8 in the highest resolution shell).
Crossvalidation, using 5%–7% of the data for the calculation of the free
R factor, was utilized throughout the model-building process in order to
monitor building bias (Kleywegt and Brunger, 1996).
Crystals of Phe-252/Gly trORAS occupy a monoclinic setting. A three-fold
redundant data set was collected to a resolution limit of 2.1 A˚ (overall Rmerge =
7.1, I/s [I] = 2.8 in the highest resolution shell) utilizing a Mar 225 CCD detector.
The structure of Phe-252/Gly trORAS was determined to 2.1 A˚ resolution by
molecular replacement using the refined coordinates of unliganded ORAS
structure as a search probe. Multiple rounds of manual model building using
XtalView (McRee, 1999) were interspersed with refinement using REFMAC5
(Murshudov et al., 1997, 1999) to complete structure refinement. Crossvalida-
tion used 5% of the data in the calculation of the free R factor.
Crystals of the trORAS-eicosanoic acid complex also occupy a monoclinic
setting. A four-fold redundant data set of the complex was collected to a Bragg
limit of 2.0 A˚ (overall Rmerge = 8.1, I/s [I] = 3.9 in the highest resolution shell) uti-
lizing a Mar 300 CCD detector. The structure of the trORAS-eicosanoic acid
complex was determined to 2.0 A˚ resolution by molecular replacement using
the refined coordinates of the unliganded trORAS structure as a search probe.
Multiple rounds of manual model building using XtalView (McRee, 1999) were
interspersed with refinement using REFMAC5 (Murshudov et al., 1997, 1999)
to complete structure refinement. The eicosanoic acid ligand was manually
built into the difference Fourier maps after the free R factor dropped
below 30%. Crossvalidation used 5% of the data in the calculation of the
free R factor.
For each of the structures, stereochemistry of the model was monitored
throughout the course of refinement using PROCHECK (Laskowski et al.,
1996). Crystal parameters, data collection parameters, and refinement statis-
tics for each of the structures are summarized in Table 1.
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